Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren in elderly patients with essential hypertension (light meal administration)
2008-001305-42Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aliskiren in essential hypertension (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline in trough mean sitting systolic blood pressure at Week 8. Started Mar 2008; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2008-001305-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001305-42.